9 completed, 1 withdrawn. 10 Phase 2, 1 Phase 3.
By phase and status
Follow danoprevir: new trials by email Literature Review of danoprevir trials Research Report on danoprevir
Trials (filtered) newest first · largest first
All 10 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects. Ravidasvir, Danoprevir, Ritonavir - HCV Phase 2 / Phase 3 Completed 425 2017-07-01 2020-07-28 Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II Danoprevir, Ritonavir, peginterferon alfa-2a - Chronic Hepatitis C Phase 2 Completed 70 2016-01-01 2018-07-26 Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan Ravidasvir, Danoprevir, Ritonavir - Chronic Hepatitis C Phase 2 Completed 38 2015-08-01 2020-10-22 A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis danoprevir + ritonavir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus] - Hepatitis C, Chronic Phase 2 Completed 61 2013-04-01 2016-11-02 A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment RO5024048, danoprevir, peginterferon alfa-2a [Pegasys] - Hepatitis C, Chronic Phase 2 Withdrawn 2012-07-01 2016-11-02 A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis RO5024048, danoprevir, peginterferon alfa-2a [Pegasys] - Hepatitis C, Chronic Phase 2 Completed 43 2012-04-01 2016-08-01 A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C Copegus, Pegasys, RO5024048 - Hepatitis C, Chronic Phase 2 Completed 381 2011-05-01 2016-11-02 A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR) Copegus placebo, RO5024048, danoprevir - Hepatitis C, Chronic Phase 2 Completed 170 2011-02-01 2016-11-02 A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection Copegus, Danoprevir, Pegasys - Hepatitis C, Chronic Phase 2 Completed 421 2010-11-01 2016-11-02 A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection Copegus, Pegasys, Placebo - Hepatitis C, Chronic Phase 2 Completed 229 2009-08-01 2016-11-02
Conditions studied Hepatitis C, Chronic (9)
Sponsors Hoffmann-La Roche (7) · Ascletis Pharmaceuticals Co., Ltd. (3)
Countries France (5) · United States (5) · Canada (4) · Germany (4) · Australia (3) · Austria (3) · Italy (3) · Brazil (2) · Mexico (2) · New Zealand (2) · Poland (2) · Puerto Rico (2) · Spain (2) · United Kingdom (2) · China (1)
Top investigators Huoling Tang, PhD (2) · Yahong Chen, Master (1)
Results publications PMID 23811112 , PMID 24637689
NIH funding 2009 (1)